Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Nimotuzumab for Resectable Recurrent Nasopharyngeal Carcinoma
NCT06912711Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2025
- Primary completion
- Apr 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 2 years. Started May 2025; status: recruiting.
02
Drugs
toripalimabnimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06912711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912711.